Background: Few studies have assessed bone health in lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation (HDT-ASCT). Therefore, we aimed to assess bone mineral density (BMD) at six different skeletal sites and to investigate associations between clinical factors and BMD in these survivors. Material and methods: Eligible lymphoma survivors were aged !18 years at diagnosis and at HDT-ASCT given between 1987 and 2008. Participants responded to questionnaires, blood samples were drawn, and a dual energy X-ray absorptiometry (DXA) was performed. Mean Z-score was applied for assessment of BMD in relation to age. Prevalence of Z-scores !À1, between À1 and À2, and À2 is reported for each measurement site and for the lumbar spine, femoral neck, and hip in combination. Likewise, T-scores were applied to assess the prevalence of normal BMD (!À1), osteopenia (between À1 and À2.5), and osteoporosis ( À2.5). Results: We included 228 lymphoma survivors, of whom 62% were males. The median age at survey was 56 years, and median observation time from HDT-ASCT was eight years. Among males, Z-scores were lower at the left femoral neck and higher at the ultra-distal (UD) radius and whole body compared to the Lunar reference database. In females, Z-scores were lower at UD radius and one-third (33%) radius and higher at the whole body. Using a classification based on Z-scores at the lumbar spine, femoral neck, and hip in combination, 25% of males and 16% of females had Z-scores <À1 and >À2, while 8% and 6% had Z-scores À2. According to T-scores, 35% of males and 41% of females had osteopenia, while 8% and 13% had osteoporosis, respectively. Conclusion: BMD was close to normal for age in this population of long-term lymphoma survivors treated with HDT-ASCT.
High-dose therapy with autologous stem cell transplantation (HDT-ASCT) has been a treatment option for selected patients with malignant lymphoma for nearly three decades [1] . HDT-ASCT has led to improved survival for groups of lymphoma patients who previously had a poor prognosis and is currently standard therapy at relapse of Hodgkin lymphoma (HL) and many types of non-Hodgkin lymphoma (NHL). HDT-ASCT is also standard primary treatment for certain types of aggressive NHL [2] .
Long-term lymphoma survivors treated with HDT-ASCT are at risk for late effects like secondary malignancies, cardiovascular diseases, and hormonal dysfunctions [3, 4] . However, few studies have assessed bone health in lymphoma survivors treated with HDT-ASCT.
Reduced bone mineral density (BMD) has been reported as prevalent after allogeneic stem cell transplantation (allo-SCT) [5] . Allo-SCT might be complicated by graft-versus-host disease (GVHD) and chronic GVHD is reported among 6-80% of allo-SCT survivors [6] . GVHD is treated with glucocorticoids and immunosuppressants, which are known to have detrimental effects on bone [5] . Although GVHD is not a problem after HDT-ASCT, this treatment might also cause disturbances in bone turnover, possibly secondary to chemotherapy, radiotherapy, hypogonadism, or malnutrition [7] . In contrast to allo-SCT, consequences of HDT-ASCT on BMD are less documented. Nevertheless, previous studies have reported reduction in BMD after HDT-ASCT for hematological malignancies after an observation time of 100 days [8] and four years [9] . BMD loss after HDT-ASCT for hematological malignancies has been shown to be most pronounced in the first year after transplantation with improvement at two years [10] . In the only study performed in a population of lymphoma survivors alone, which was questionnaire-based and did not include BMD measurements, self-reported prevalence of osteoporosis tended to be higher in lymphoma survivors compared to siblings at a median of six years after HDT-ASCT [11] .
Low BMD is associated with a raised risk of fractures leading to increased morbidity and mortality [12] . Information on prevalence and predisposing factors for low BMD in long-term lymphoma survivors treated with HDT-ASCT is important in defining risk groups of survivors who might need individual preventive measures and follow-up.
Based on this background, we aimed to assess bone health in lymphoma survivors treated with HDT-ASCT by measuring BMD and by investigating associations between clinical factors and BMD.
Material and methods

Study design and participants
This study is part of a cross-sectional multicenter study investigating late effects after HDT-ASCT for HL or NHL in Norway between 1987 and 2008 [1, 4] . A total of 399 lymphoma survivors, identified through medical records and registries at each of the hospitals, were eligible for this study. They were contacted by mail and, in case of no response; they received a reminder after six weeks.
Participants underwent a comprehensive outpatient medical examination between February 2012 and April 2014. The examination was performed over two days and included dual energy X-ray absorptiometry (DXA) measurements, collection of blood samples for assessment of hormonal levels, and questionnaires. Further, participants underwent a standardized interview by experienced clinicians including registration of comorbidities. For the present study, only participants aged !18 years at diagnosis and examined by a Lunar Prodigy DXA were included.
Treatment
Data on treatment for each survivor were obtained from patient records and institutional radiotherapy registries. From 1987 until 1995, the high-dose regimen consisted of total body irradiation (1.3 Gy Â10) in combination with high-dose cyclophosphamide, while chemotherapy [carmustine, etoposide, cytarabine, and melphalan (BEAM)] has been given alone since 1995 [1, 13] . The number of treatment lines, consisting of chemotherapy and/or radiotherapy before HDT-ASCT, was registered. For this study, we recorded if the survivors had received radiotherapy or not, and whether or not the radiotherapy had been given to the infradiaphragmatic region. Exact radiation target fields were not specified.
Measurement of bone mineral density and classification of scores
The BMD examination was performed using a narrow fan beam DXA densitometer (GE Healthcare Lunar Prodigy). Z-and T-scores were estimated by comparison to the Lunar reference database incorporated in the software. The Lunar reference database is provided by the manufacturer of the bone densitometry equipment and includes BMD data from healthy subjects from the general American population.
The DXA measurements were performed at three different centers (Oslo University Hospital, Haukeland University Hospital, and the University Hospital of North Norway) and analyzed with the software versions 14.10 (n ¼ 180), 13 .40 (n ¼ 27) and 13.60 (n ¼ 21) (GE Healthcare, Lunar Corp., Madison, WI). All participating centers had procedures for calibrations for BMD to avoid systematic errors between different software versions.
BMD measures grams of mineral per square centimeter (g/ cm 2 ). Values for the anterior-posterior lumbar spine (L2-L4), left femoral neck, left total hip, ultra-distal (UD) radius, onethird (33%) radius, and whole body were used for this study. BMD was measured at the non-dominant forearm. BMD values for UD radius and 33% radius were not included for participants examined at Haukeland University Hospital.
For Z-scores, values À2 were defined as below the expected range for age and gender. T-scores were defined as standard deviations (SD) above or below mean for healthy men or women between 20 and 40 years of age. According to the World Health Organization, normal BMD was defined as a T-score !À1, osteopenia as a T-score between À1 and À2.5, and osteoporosis as a T-score À2.5.
In lymphoma survivors treated with HDT-ASCT, Z-scores are the most relevant measure as they compare the lymphoma survivors' BMD to the BMD of healthy individuals of the same age and gender. This comparison enables us to investigate the possible association between HDT-ASCT and BMD. However, in order to describe the study population, we also decided to include T-scores and thereby classify the participants with osteopenia and osteoporosis.
As the International Society for Clinical Densitometry uses BMD in the lumbar spine and hip to define osteoporosis [14] , we used the lowest Z-and T-scores at the lumbar spine, femoral neck and total hip to classify participants. As only 16 participants had Z-scores À2 in one or more of these regions, we defined low BMD as a Z-score <À1 as outcome in logistic regression analyses.
Questionnaires and clinical assessments
Participants responded to a questionnaire covering smoking habits, alcohol consumption, and physical activity. For this, we used questions that were originally designed for the third population-based health survey of Nord-Trøndelag County (the HUNT surveys) [15] . Data on menopausal status and use of hormone substitution or other medications were also obtained from the questionnaires, while data on body weight and height were obtained from the DXA forms.
Smoking was dichotomized into current (including occasional smokers) versus prior or never. Based on reported alcohol consumption within the last 14 days, participants were grouped to have no consumption (0 units), low/moderate consumption (1-14 units) and high consumption (15 units or more) [16] . Body mass index (BMI) was calculated as body weight divided by height squared (kg/m 2 ). Physical activity was dichotomized based on whether or not participants fulfilled recommendations for physical activity of performing at least 150 minutes of moderate, or 75 minutes of vigorous intensity, physical activity per week [17] .
Blood samples were drawn at 8 a.m., and used to analyze the hypothalamic-pituitary-gonadal axis in males. The analyses were performed using Roche E-platform (Roche Diagnostics). Male gonadal hormone status was grouped into: (1) normal or elevated follicle-stimulating hormone (FSH) only; (2) low testosterone and/or elevated luteinizing hormone (LH); and (3) testosterone substitution therapy. Ageadjusted reference values were used for the male gonadal hormones [18] . Females reporting menopause before the age of 42 years were classified as having premature ovarian failure.
Statistical analyses
Continuous data were described as means with 95% CIs or medians and ranges. Categorical data were described using frequencies and proportions.
Comparison of Z-scores to the Lunar reference database was performed by one sample t-tests. Z-scores were close to normally distributed and analyzing with non-parametric tests did not change the results. Comparisons between participants and non-participants were performed by v 2 -and t-tests. Mann-Whitney U-test was used for non-normal distributions.
Univariate logistic regression analysis was performed with low BMD, defined as Z-score <À1 for lumbar spine, femoral neck, or total hip, as the dependent variable and demographic characteristics, clinical variables (lymphoma type, treatment lines, conditioning regimen, infradiaphragmatic radiotherapy, undergoing allo-SCT, and relapse), and lifestyle parameters (smoking, alcohol consumption, and physical activity) as independent variables. Furthermore, univariate logistic regression analysis was performed by gender to investigate associations between gonadal hormone status and low BMD.
In the multivariate logistic regression analyses, gender, age at HDT-ASCT, and observation time after HDT-ASCT were all included as explanatory variables because of clinical relevance. Other variables were included if the p value was <0.1 in the univariate analysis.
The strengths of associations were presented as odds ratios (OR) with 95% CIs. A p value <0.05 was considered statistically significant (all tests were two-sided). All analyses were performed using SPSS version 21.0.
Ethical considerations
The Regional Committee for Medicine and Health Research Ethics of South-East Norway approved the study. All participants provided written informed consent.
Results
Of the 399 invited lymphoma survivors, 87 declined to participate or did not respond. Further, 33 lymphoma survivors from Trondheim University Hospital were excluded due to use of a Hologic bone densitometer, 47 lymphoma survivors were excluded due to missing DXA scans, three due to age less than 18 years at time of diagnosis, and one due to current use of high-dose prednisolone. Thus, 228 lymphoma survivors fulfilled the inclusion criteria for the present study and consented to participate. Of these, 180 were examined at Oslo University Hospital, 27 at Haukeland University Hospital, and 21 at the University Hospital of North Norway.
The primary diagnosis (NHL or HL), age at survey, sex, and observation time from HDT-ASCT did not differ between participants and non-participants (data not shown).
Participants' characteristics
The participants' demographic, clinical, and treatment characteristics are displayed in Table 1 . One hundred and forty-two (62%) of the participants were male, median age at diagnosis was 42.6 (range 18-66) years, median age at HDT-ASCT was 45.8 (range 19-66) years, and median observation time from HDT-ASCT to survey was 8.3 (range 3-24) years. Six participants (one male and five females) were treated with bisphosphonates for osteoporosis.
Forty-six (20%) of the participants were smoking daily or occasionally and 25 (11%) had a high alcohol consumption. A total of 103 (46%) participants fulfilled the recommendations for physical activity.
Among males, 77 (57%) had normal gonadal function or elevated FSH only, 51 (37%) had low testosterone and/or elevated LH, and eight (6%) were treated with testosterone substitution therapy.
Forty-six (55%) females were currently, or had previously been, treated with hormone replacement therapy (HRT). A total of 26 (31%) females had premature ovarian failure, of which 19 (73%) had previously been, or were currently, treated with HRT.
Prevalence of osteopenia and osteoporosis
Based on the lowest score at lumbar spine, femoral neck and total hip, categorizations of Z-and T-scores for males and females are displayed in Figure 1 . Of males, 25% had Z-scores between À1 and À2 and 8% had Z-scores À2. According to T-scores, 35% had osteopenia and 8% had osteoporosis. Among females 16% had Z-scores between À1 and À2 and 6% had Z-scores À2. According to T-scores, 41% had osteopenia and 13% had osteoporosis. The main results presented in Figure 1 did not change if participants using systemic lowdose corticosteroids (n ¼ 4), bone resorption inhibitors (n ¼ 5), or both (n ¼ 1) were excluded.
Percentages of males and females with the different categories of Z-and T-scores at the six measurement sites are illustrated in Figure 2 .
Bone mineral density levels Table 2 lists the mean BMD values and Z-scores for the six assessed skeletal sites for males and females separately.
For males, mean Z-scores were significantly lower at the left femoral neck and higher at UD radius and whole body compared to the Lunar reference database. Among the males there were no significant differences in Z-scores for the six measurement sites according to gonadal hormone status (data not shown).
Among females, mean Z-scores were significantly lower at UD radius and 33% radius, while they were significantly higher at whole body compared to the Lunar reference database. There were no significant differences in Z-scores for the six measurement sites among females with premature menopause versus not, or between females treated with HRT versus not (data not shown).
Logistic regression analyses
In univariate regression analysis, the risk for low BMD (Zscore <À1) in the lumbar spine, femoral neck, or total hip, tended to be increased for survivors treated with HDT-ASCT for primary or relapsed aggressive NHL compared to survivors treated with HDT-ASCT for HL (OR 2.23, 95% CI 0.97-5.13) ( Table 3 ). In the multivariate analysis, the risk was significantly increased (OR 2.45, 95% CI 1.01-5.98). No other significant associations between clinical variables and a Zscore <À1 were observed. Further, there were no significant associations between current smoking, alcohol use, or physical activity and a Z-score <À1 (data not shown).
In gender-specific univariate regression analyses, no significant association between gonadal hormone status and risk for low BMD (Z-score <À1), in the lumbar spine and/or femoral neck, and/or total hip, was demonstrated in males (data not shown). Females with premature ovarian failure, however, tended to have an increased risk for low BMD (OR 2.59, 95% CI 0.90-7.46) compared to those with menopause at an age of 42 years or older.
Even though the DXA measurements were performed at three different centers, significance levels for mean Z-scores and regression analyses did not change if only participants examined at Oslo University Hospital (n ¼ 180) were included (data not shown).
Discussion
In this study we demonstrated that BMD levels in lymphoma survivors were close to normal for age at a median observation time of eight years after HDT-ASCT. Z-scores in males were lower at the femoral neck, while they were higher at UD radius and whole body compared to the Lunar reference database. Among females, Z-scores were lower at UD radius and 33% radius and higher for the whole body. As our results were heterogeneous, we cannot conclude that there is a general association between HDT-ASCT and low BMD.
The interpretation of BMD levels is intricate and any comparison to previous studies must be done with caution. Classifications and prevalence of abnormal values depend on the skeletal sites measured, whether Z-or T-scores are given, and the reference population used [19, 20] . Z-scores compare the participant's BMD to that of an individual of the same age, sex and weight. Therefore we find Z-scores relevant for describing BMD in our study population of long-term lymphoma survivors who might be at risk for secondary bone loss. In contrast, the data including T-scores have to be interpreted with great caution as the prevalence of osteopenia and osteoporosis is expected to rise with increasing age, and as there are few studies for comparison.
BMD of the total hip and whole body has previously been measured in more than 5000 randomly selected Norwegian men and women aged 47-50 years and 71-75 years [21] . A higher proportion of middle-aged and elderly males and elderly females had a Z-score <À1, compared to the Lunar reference database [21] . The Lunar reference database has, however, been perceived to be suitable for clinical use in the Norwegian population [21] .
The prevalence of osteoporosis in our study is close to the prevalence reported in a study including more than 4600 males and females aged 30-89 years from the general Norwegian population [22] . The study reported a prevalence of osteoporosis for all age-groups combined of 8% at the femoral neck and 4% at the total hip in males, and 11% at the femoral neck and 8% at the total hip in females. We found a prevalence of osteoporosis of 6% at the femoral neck and 4% at the total hip in males and 6% at both the femoral neck and total hip in females. The participants in the study by Emaus et al. [22] were approximately 10 years older compared to participants in our study, and this might explain why they reported a higher prevalence of osteoporosis in females.
Gonadal hormone dysfunction and premature ovarian failure are common late effects after treatment for lymphoma in females that might lead to osteoporosis [23] . In spite of this, we found BMD levels in females to be close to normal for age. This may partly be explained by institution of HRT to a high percentage of females (73%) reporting premature ovarian failure. Initiation of HRT in these women indicates that clinicians are aware of this late effect. Male hypogonadism as a consequence of androgen suppression therapy for prostate cancer is associated with reduction in BMD, but it is unclear whether the more subtle gonadal dysfunction in males treated for lymphoma might contribute to osteoporosis [23] . Previous studies assessing BMD in survivors after HDT-ASCT have included patients with various hematological malignancies [8] [9] [10] 24, 25] . To our knowledge, this cross-sectional study is the first to assess BMD in a population of only long-term lymphoma survivors treated with HDT-ASCT.
A longitudinal study measuring BMD in 180 patients treated with HDT-ASCT for hematological malignancies, reported that bone loss was most pronounced in the first year post-transplant. From six months to 24 months after transplantation, the incidence of osteoporosis in the lumbar spine (L1-L4) declined from 32% to 12%, and the incidence of osteopenia fell from 41% to 33% [10] . In our study, the prevalence of osteoporosis and osteopenia in L2-L4 was even lower, 3% and 19% in males and 10% and 25% in females, respectively. This might be due to the long observation time of eight years in our study, giving the bone mass longer time to restore.
Three smaller studies have also investigated BMD in patients treated with HDT-ASCT for mainly hematological malignancies. The first study evaluated BMD in 29 patients at a median of five years after HDT-ASCT and concluded that the BMD values were normal for age and gender [25] . The second study assessed BMD in 44 patients treated with HDT-ASCT and reported a decline in BMD at the hip three and six months after treatment. However, at 24 months, the BMD at trochanter and lumbar spine had returned to baseline values, while it remained reduced at the femoral neck [24] . The third study measured BMD in 64 patients with a median age of 50 years four years after HDT-ASCT, and reported that 61% had osteopenia or osteoporosis in the lumbar spine and/or femoral neck. Mean BMD at the femoral neck was lower than in healthy young adults and age-and sex-matched controls, while there was no significant difference in mean BMD at the lumbar spine [9] . Two previous studies have also reported reduced BMD levels in the femoral neck after HDT-ASCT [9, 24] , in accordance with our finding that Z-scores were reduced at the femoral neck in males.
A limitation of our study is the cross-sectional design and consequently lack of baseline BMD values. Further, we have no control group, and have applied the Lunar reference database incorporated in the software for comparison. Z-scores of the Lunar reference database have been reported to deviate to some degree from the values in the Norwegian population [21] . A second limitation is that we did not register fracture rates.
DXA scans were performed at three different institutions, but results regarding levels of mean Z-scores and regression analyses did not change if only participants examined at Oslo University Hospital (n ¼ 180) were included.
Further studies, preferably with a prospective design and including control groups, are needed to investigate BMD levels in lymphoma survivors after HDT-ASCT. We found an increased risk for low BMD (Z-score <À1) in the lumbar spine, femoral neck, or total hip for survivors treated for aggressive NHL compared to survivors treated for HL and this might be interesting to explore. As increasing age alone causes bone loss, BMD should be assessed in long-term survivors after HDT-ASCT to reveal if bone loss is accelerated with age in these survivors compared to a reference population.
In conclusion, BMD levels in this population of long-term lymphoma survivors treated with HDT-ASCT were close to normal for age. Thus, we cannot recommend measurement of BMD on a regular basis in this population. However, BMD measurement might be warranted in lymphoma survivors with additional risk factors such as hypogonadism, familial disposition, or low body weight.
